209 related articles for article (PubMed ID: 26921250)
1. Cdc7 is a potent anti-cancer target in pancreatic cancer due to abrogation of the DNA origin activation checkpoint.
Huggett MT; Tudzarova S; Proctor I; Loddo M; Keane MG; Stoeber K; Williams GH; Pereira SP
Oncotarget; 2016 Apr; 7(14):18495-507. PubMed ID: 26921250
[TBL] [Abstract][Full Text] [Related]
2. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
[TBL] [Abstract][Full Text] [Related]
3. Cdc7-dependent and -independent phosphorylation of Claspin in the induction of the DNA replication checkpoint.
Rainey MD; Harhen B; Wang GN; Murphy PV; Santocanale C
Cell Cycle; 2013 May; 12(10):1560-8. PubMed ID: 23598722
[TBL] [Abstract][Full Text] [Related]
4. Xenopus Cdc7 executes its essential function early in S phase and is counteracted by checkpoint-regulated protein phosphatase 1.
Poh WT; Chadha GS; Gillespie PJ; Kaldis P; Blow JJ
Open Biol; 2014 Jan; 4(1):130138. PubMed ID: 24403013
[TBL] [Abstract][Full Text] [Related]
5. p53 gain-of-function mutations increase Cdc7-dependent replication initiation.
Datta A; Ghatak D; Das S; Banerjee T; Paul A; Butti R; Gorain M; Ghuwalewala S; Roychowdhury A; Alam SK; Das P; Chatterjee R; Dasgupta M; Panda CK; Kundu GC; Roychoudhury S
EMBO Rep; 2017 Nov; 18(11):2030-2050. PubMed ID: 28887320
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
Rodriguez-Acebes S; Proctor I; Loddo M; Wollenschlaeger A; Rashid M; Falzon M; Prevost AT; Sainsbury R; Stoeber K; Williams GH
Am J Pathol; 2010 Oct; 177(4):2034-45. PubMed ID: 20724597
[TBL] [Abstract][Full Text] [Related]
9. Identification of Novel Cdc7 Kinase Inhibitors as Anti-Cancer Agents that Target the Interaction with Dbf4 by the Fragment Complementation and Drug Repositioning Approach.
Cheng AN; Lo YK; Lin YS; Tang TK; Hsu CH; Hsu JT; Lee AY
EBioMedicine; 2018 Oct; 36():241-251. PubMed ID: 30293817
[TBL] [Abstract][Full Text] [Related]
10. p53 controls CDC7 levels to reinforce G1 cell cycle arrest upon genotoxic stress.
Tudzarova S; Mulholland P; Dey A; Stoeber K; Okorokov AL; Williams GH
Cell Cycle; 2016 Nov; 15(21):2958-2972. PubMed ID: 27611229
[TBL] [Abstract][Full Text] [Related]
11. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
Kulkarni AA; Kingsbury SR; Tudzarova S; Hong HK; Loddo M; Rashid M; Rodriguez-Acebes S; Prevost AT; Ledermann JA; Stoeber K; Williams GH
Clin Cancer Res; 2009 Apr; 15(7):2417-25. PubMed ID: 19318489
[TBL] [Abstract][Full Text] [Related]
12. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds.
Sasi NK; Tiwari K; Soon FF; Bonte D; Wang T; Melcher K; Xu HE; Weinreich M
PLoS One; 2014; 9(11):e113300. PubMed ID: 25412417
[TBL] [Abstract][Full Text] [Related]
13. Cdc7 kinase mediates Claspin phosphorylation in DNA replication checkpoint.
Kim JM; Kakusho N; Yamada M; Kanoh Y; Takemoto N; Masai H
Oncogene; 2008 May; 27(24):3475-82. PubMed ID: 18084324
[TBL] [Abstract][Full Text] [Related]
14. ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition.
Rainey MD; Bennett D; O'Dea R; Zanchetta ME; Voisin M; Seoighe C; Santocanale C
Cell Rep; 2020 Sep; 32(9):108096. PubMed ID: 32877678
[TBL] [Abstract][Full Text] [Related]
15. Cdc7 as a potential new target for cancer therapy.
Ito S; Taniyami C; Arai N; Masai H
Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
[TBL] [Abstract][Full Text] [Related]
16. Quantitative proteomics reveals a "poised quiescence" cellular state after triggering the DNA replication origin activation checkpoint.
Mulvey C; Tudzarova S; Crawford M; Williams GH; Stoeber K; Godovac-Zimmermann J
J Proteome Res; 2010 Oct; 9(10):5445-60. PubMed ID: 20707412
[TBL] [Abstract][Full Text] [Related]
17. DNA Replication Dynamics and Cellular Responses to ATP Competitive CDC7 Kinase Inhibitors.
Rainey MD; Quachthithu H; Gaboriau D; Santocanale C
ACS Chem Biol; 2017 Jul; 12(7):1893-1902. PubMed ID: 28560864
[TBL] [Abstract][Full Text] [Related]
18. Effects of CDC7 gene silencing and Rituximab on apoptosis in diffuse large B cell lymphoma cells.
Hou Y; Wang HQ; Ba Y
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2027-34. PubMed ID: 22806309
[TBL] [Abstract][Full Text] [Related]
19. ATR-dependent activation of p38 MAP kinase is responsible for apoptotic cell death in cells depleted of Cdc7.
Im JS; Lee JK
J Biol Chem; 2008 Sep; 283(37):25171-25177. PubMed ID: 18625709
[TBL] [Abstract][Full Text] [Related]
20. Molecular architecture of the DNA replication origin activation checkpoint.
Tudzarova S; Trotter MW; Wollenschlaeger A; Mulvey C; Godovac-Zimmermann J; Williams GH; Stoeber K
EMBO J; 2010 Oct; 29(19):3381-94. PubMed ID: 20729811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
